期刊
MOLECULAR ONCOLOGY
卷 11, 期 7, 页码 718-738出版社
WILEY
DOI: 10.1002/1878-0261.12091
关键词
clinical trials; EMT; MET; metastasis; preclinical models; therapy resistance
类别
资金
- Spanish Ministerio de Economia y Competitividad [SAF2013-44739-R, SAF2016-76504-R]
- Spanish Instituto de Salud Carlos III (EU-FEDER funds) [RETIC-RD12/0036/0007, CIBER-ONC-CB16/12/00295, PI13/00132, PI16/00134]
- Worldwide Cancer Research (WWCR) [WWCR 16-0295]
- Fundacion Cientifica AECC
Epithelial/mesenchymal transition (EMT) has emerged as a key regulator of metastasis by facilitating tumor cell invasion and dissemination to distant organs. Recent evidences support that the reverse mesenchymal/epithelial transition (MET) is required for metastatic outgrowth; moreover, the existence of hybrid epithelial/mesenchymal (E/M) phenotypes is increasingly being reported in different tumor contexts. The accumulated data strongly support that plasticity between epithelial and mesenchymal states underlies the dissemination and metastatic potential of carcinoma cells. However, the translation into the clinics of EMT and epithelial plasticity processes presents enormous challenges and still remains a controversial issue. In this review, we will evaluate current evidences for translational applicability of EMT and depict an overview of the most recent EMT in vivo models, EMT marker analyses in human samples as well as potential EMT therapeutic approaches and ongoing clinical trials. We foresee that standardized analyses of EMT markers in solid and liquid tumor biopsies in addition to innovative tools targeting the E/M states will become promising strategies for future translation to the clinical setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据